Recent studies suggest that metformin, which is commonly used as an oral anti-hyperglycemic agent of the biguanide family, may reduce cancer risk and improve prognosis, but the mechanisms by which metformin affects various cancers, including gastric cancer, remains unknown. The goal of the present study was to evaluate the effects of metformin on human gastric cancer cell proliferation in vitro and in vivo, and to study microRNAs (miRNAs) associated with metformin's anti-tumor effect. We used 
Introduction

Xenograft model analysis
Animal experiments were performed according to the guidelines of the Committee on Experimental Animals of Kagawa University. We purchased 30 male athymic mice (BALB/c-nu/nu; 8 weeks old; 20-25 g) from Japan SLC (Hamamatsu, Japan). The animals were maintained under specific pathogen-free conditions using a laminar airflow rack and had continuous free access to sterilized food (gamma-ray-irradiated food, CL-2; CLEA Japan, Tokyo, Japan) and autoclaved water. Each mouse was inoculated with MKN74 cells (5×10 6 cells/animal) subcutaneously on the flank regions of the mouse. Two weeks later, the xenografts were identifiable as a mass of more than 6 mm in maximal diameter in all recipients. The animals were randomly assigned to three groups. These groups were treated with 1 mg metformin, 2 mg metformin, or control (PBS only), respectively.
The metformin-treated group was injected 5 times a week intraperitoneally (i.p.) at 1 mg/body or 2 mg/body per day for 4 weeks. Only PBS was administered to the control group (n=10) for 4 weeks. After the initiation of the metformin administration, the tumor growth was monitored by the same investigators (K.K., T.M.), and the tumorigenesis of gastric cancer was monitored every day. Tumor size was measured weekly by measuring the two greatest perpendicular tumor dimensions. To examine the Technologies). Samples were first normalized relative to 28sRNA and baseline corrected to the median of all samples.
Replicate data were consolidated into two groups: those from metformin-treated animals and those from control animals, and were organized by using the hierarchical clustering and ANOVA functions in the GeneSpring software. Hierarchical clustering was done by the use of the clustering function (condition tree) and Euclidean correlation as a distance metric. Two-way ANOVA analysis and asymptotic p-value computation without any error correction on the samples were performed to search for the miRNAs that varied most prominently across the different groups. The p-value cutoff was set to 0.05. Only changes >50% at least one of the time points for each sample were considered significant. All the analyzed data were scaled by global normalization. The statistical significance of differentially expressed miRNAs was analyzed by Student's t-test.
Results
Metformin inhibits the proliferation of human gastric cancer cell growth
To evaluate the effect of the growth activity of metformin on human gastric cancer cells in vitro, we examined metformin's effect on proliferation in three gastric cancer cell lines: MKN1, MKN45, MKN74. Cells were grown in 10% fetal bovine serum (FBS) and treated with 1, 5 and 10 mM metformin or, as a control, without metformin.
The cell proliferation assay was performed 3 days after the addition of the agents. As shown in Fig. 1A , metformin led to a dose-dependent and strong inhibition of cell proliferation in all gastric cancer cell lines, with 49%, 35% and 51% decreases in the viability of MKN1, MKN45 and MKN 74 cells, respectively, with 10 mM metformin.
To discern the direct relationship between the decrease in cell viability and the inhibition of cell proliferation, we followed the course of proliferation over 3 days after the addition of metformin. Metformin (0, 1, 5 and 10 mM) led to a decrease in cell proliferation in a dose-and time-dependent manner in all three cell lines tested (Fig. 1B) .
Together, the results show that metformin inhibits gastric cancer proliferation.
Effects of metformin on cell-cycle regulatory proteins in MKN74
To study whether or not metformin affects the MKN74 cell cycle, Western blotting Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 5, 2012; DOI: 10.1158/1535-7163. analysis was used to examine the expression of various cell-cycle-related molecules in MKN74 with and without metformin treatment. Cells were treated with 10 mM metformin or without metformin for 24-72 h. The most remarkable change was the loss of cyclin D 1 , a key protein implicated in the transition of the G0/G1 phase. In short, the cyclin D 1 level declined slightly at 24 h after the addition of metformin and was no longer detectable at 48 h and 72 h ( Fig. 2A) . The level of phosphorylated pRb also decreased progressively in metformin-treated cells. As shown in Fig. 2A , we then studied the expression of other cell-cycle-related proteins (Cdk4, Cdk6, cyclin E and Cdk2) implicated in the G0/G1 transition. Although Cdk6, the catalytic subunit of cyclin D1, was decreased at 48 and 72 h after the addition of metformin, Cdk4 was slightly decreased at 48 and 72 h after. Cyclin E was unchanged at 24 h after metformin treatment, but was decreased at 48 and 72 h after. The catalytic subunit of cyclin E, Cdk2, was also slightly decreased at 48 and 72 h after the addition of metformin. The level of phosphorylated Rb also decreased progressively in metformin-treated cells. On the other hand, total Rb was the same in cell line irrespective of metformin treatment.
These events were detected in other cancer cell lines, such as MKN1 and MKN45 (data not shown). presence of metformin, the cell-cycle progression was examined by flow cytometry. We treated proliferating MKN74 cells with 10 mM metformin for different durations. After the addition of 10 mM metformin, an increasing number of cells started to accumulate in G 0 /G 1 , 63.0% after 48 h and 63.5% by 72 h (Fig. 2B) . In parallel, after the addition of 10 mM metformin, we observed reductions in the percentage of cells in the S phase and G 2 /M phase (Fig. 2B ). These data suggest that metformin inhibits cell-cycle progression from G 0 /G 1 into S phase, resulting in G1 cell-cycle arrest.
Metformin inhibits tumor proliferation in vivo
In order to determine whether or not metformin could affect tumor growth in vivo, we injected nude mice subcutaneously (s.c.) with MKN 74 cells. Metformin was injected daily intraperitoneally (i.p.) at 1 mg or 2 mg per day.
On the basis of the integrated values of the tumor growth curves, i.p. administration of metformin led to the substantial inhibition of tumor growth, by 41% (1 mg/day) and 78% (2 mg/day) ( Fig. 3A and B, p=0.0207, one-way ANOVA). These growth rates were significantly above those of the control (p<0.01 and p<0.004, respectively). In addition, 2 mg metformin treatment significantly inhibited tumor growth compared with 1 mg metformin-treated mice (p<0.007). In this study, metformin exhibited no apparent changes in mice and did not affect their weight (data not shown). All animals were alive during the experiment.
In order to determine whether or not metformin also affects cell-cycle regulatory protein levels in vivo, we analyzed protein expression using Western blotting analysis in tumors obtained from the xenograft experiments. Metformin reduced significantly the levels of these proteins (phosphorylated Rb, cyclin D1, Cdk2, Cdk4, Cdk6 and cyclin E) in treated tumors compared to controls (Fig. 3C ). On the other hand, total Rb was the same in cell line irrespective of metformin. These results suggest that, similar to the results of the in vitro observations ( Fig. 2A) , metformin decreases tumor growth by reducing cell-cycle regulatory protein levels, resulting in G1 cell-cycle arrest.
Differences in phosphorylated-receptor tyrosine kinases p-(RTKs) in vitro and in vivo treated with and without metformin
We used a phosphorylated-RTK array system to identify the "key RTKs" associated with metformin's anti-tumor effect. By using the antibody array (Fig. 4A) No.GSE30289). In Tables 1 and 2 , the 7 miRNAs marked with a dagger were matched with ones from both cultured cells and xenograft tissues after metformin treatment.
Unsupervised hierarchical clustering analysis, using Pearson's correlation, showed that cell lines in vitro and tumorous tissues in vivo treated with metformin clustered together and separately from the untreated cell lines (Fig. 5A ) and tissues (Fig. 5B ).
These subsets of 51 microRNAs in cell lines and 43 miRNAs in tissues were found to exhibit >1.5fold alterations in expression levels between the metformin-treated and control groups. 
Discussion
The incidence and mortality rate of gastric cancer have decreased dramatically over the past several decades. Nonetheless, the disease remains a major public health issue as the second leading cause of cancer death worldwide (16) . Apart from potentially curative surgery, chemotherapy and radiochemotherapy may be applied at advanced stages in gastric cancer, but neither can cure the disease in such cases, and the prognosis is poor. Thus there is strong demand for new curative approaches to gastric cancer therapy.
The role of the antidiabetic drug metformin in glucose and fatty acid metabolism is very well known (17, 18) . In mice, at doses of 1-3 mg per day, it stimulates glucose uptake and increases fatty acid oxidation in muscle and liver with no side effects (5).
Recent data suggest that metformin could protect from cancer and inhibit proliferation in various cancer cell lines, such as breast cancer (11), glial cancer (9) and prostate cancer (5). However, the anti-tumor effect of metformin for gastric cancer remains unknown. Here we show that metformin not only is a very potent inhibitor of human gastric cancer cell growth but also inhibits tumorigenesis in a xenograft model when Our in vitro study was performed using a higher dose of metformin than the human therapeutic concentration (6 to 30 μM). The use of such higher doses has been the subject of criticism of similar studies in other cancer cell types, such as breast (6) inhibits the growth of lung cancer (43). Especially, the expression of hsa-mir-638 in metformin-treated cells was 3.3 times higher than that in untreated cells. Hsa-mir-638 is one of the miRNAs most abundantly expressed in normal serum. Although has-mir-638's physiological significance is not adequately known, one report shows decreased expression of hsa-mir-638 in gastric cancer tissues (44). Thus, our data suggest that hsa-mir-638 may be a candidate for a new therapeutic target in gastric cancer.
In the present study, we found only 7 matched miRNAs extracted from cultured 
Metformin is a drug widely used for the treatment of type 2 diabetes with limited side effects. Therefore, metformin may become a novel and effective therapy for the treatment and long-term management of gastric cancer, providing additional benefits at low cost. NOTE: MiRNAs marked with a dagger were matched to miRNAs extracted from cultured cells and tumorous tissues after treatment with metformin. Table 2 Fold ( 
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